{"entity":{"id":"endometrial-molecular-classes","kind":"term","name":"Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)","aka":["ProMisE","ProMisE classifier","molecular classification of endometrial cancer","TCGA endometrial subtypes","WHO 2020 endometrial molecular classification","endometrial molecular class","molecular class"],"tldr":"Four groups defined by a few tests that predict outcome better than the microscope: POLE-mutated (excellent), mismatch-repair deficient, p53-abnormal (worst), and 'no specific profile'.","summary":"From TCGA (Nature 2013) via the ProMisE classifier (Talhouk 2015) into the WHO 2020 classification and ESGO/ESTRO/ESP 2021 guidelines. POLE-ultramutated (~7%) almost never relapses and may need no adjuvant therapy; MMRd (~25-30%) responds to immunotherapy; p53abn (~15%; includes most serous) benefits from chemotherapy (PORTEC-3) and often carries HER2 amplification; NSMP (~50%) is heterogeneous, with L1CAM and ER status refining risk. Molecular-class-directed adjuvant trials (RAINBO programme, PORTEC-4a) are ongoing.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Endometrial_cancer","links":[{"label":"TCGA, Nature 2013","url":"https://www.nature.com/articles/nature12113"}],"tags":[],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":["tp53","her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["msi"],"trials":["portec-3"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Cancer biology"},"route":"/terms/endometrial-molecular-classes/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"endometrial-nsmp","kind":"cancer","name":"Endometrial cancer with no specific molecular profile","route":"/cancers/endometrial-nsmp/"},{"id":"endometrial-mmr-deficient","kind":"cancer","name":"Mismatch-repair-deficient endometrial cancer","route":"/cancers/endometrial-mmr-deficient/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"endometrial-pole-ultramutated","kind":"cancer","name":"POLE-ultramutated endometrial cancer","route":"/cancers/endometrial-pole-ultramutated/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"term":[{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"nsmp","kind":"term","name":"No specific molecular profile (NSMP) endometrial cancer","route":"/terms/nsmp/"},{"id":"pole-ultramutation","kind":"term","name":"POLE ultramutation (POLEmut)","route":"/terms/pole-ultramutation/"}],"trial":[{"id":"portec-3","kind":"trial","name":"PORTEC-3","route":"/trials/portec-3/"}],"idea":[{"id":"idea-her2-adc-serous-endometrial","kind":"idea","name":"HER2 ADCs as standard for HER2-positive serous endometrial cancer","route":"/ideas/idea-her2-adc-serous-endometrial/"},{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/"}],"pathway":[{"id":"mismatch-repair-msi","kind":"pathway","name":"Mismatch repair & microsatellite instability","route":"/pathways/mismatch-repair-msi/"}],"drug":[{"id":"ventana-mmr-rxdx","kind":"drug","name":"VENTANA MMR RxDx Panel","route":"/drugs/ventana-mmr-rxdx/"}]}}